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ABSTRACT Zinc finger domains are structures that me-
diate sequence recognition for a large number of DNA-binding
proteins. These domains consist of sequences of amino acids
containing cysteine and histidine residues tetrahedrally co-
ordinated to a zinc ion. In this report, we present a means to
selectively inhibit a zinc finger transcription factor with
cobalt(III) Schiff-base complexes. 1H NMR spectroscopy con-
firmed that the structure of a zinc finger peptide is disrupted
by axial ligation of the cobalt(III) complex to the nitrogen of
the imidazole ring of a histidine residue. Fluorescence studies
reveal that the zinc ion is displaced from the model zinc finger
peptide in the presence of the cobalt complex. In addition,
gel-shift and filter-binding assays reveal that cobalt com-
plexes inhibit binding of a complete zinc finger protein,
human transcription factor Sp1, to its consensus sequence.
Finally, a DNA-coupled conjugate of the cobalt complexes
selectively inhibited Sp1 in the presence of several other
transcription factors.
Zinc finger domains consist of sequences of amino acids
containing cysteine and histidine residues tetrahedrally coor-
dinated about a zinc ion. Detailed structural information
supports the existence of multiple classes of zinc fingers (1–3),
and these include domains in which the zinc ion is coordinated
by Cys2His2 (e.g., TFIIIA), Cys3His (e.g., retroviral nucleo-
capsid proteins), or Cys4 (e.g., glucocorticoid receptor). The
zinc finger motif is crucial for specific DNA recognition by zinc
finger transcription factors.
In this work, we describe a family of cobalt(III)-Schiff-base
complexes [Co(III)-sb] that are effective zinc finger inhibitors.
Related complexes were shown to have potent anti-
inflammatory properties (4). The general structure of this class
of complexes is shown in Fig. 1. We investigated the effect of
a series of Co(III) complexes, cobalt(III) complex of bis(ace-
tylacetone)ethylenediimine [acacen], reacted with zinc finger
proteins including a synthetic peptide representing the first
zinc finger region from HIV-1 nucleocapsid protein (NCp7)
and Sp1, a human zinc finger transcription factor (5). CD and
1H NMR studies were performed to determine perturbations
to zinc finger structure caused by reaction with the Co(III)-sb
complexes. Gel-shift and filter-binding assays revealed that the
Co(III)-sb effectively inhibited DNA binding by Sp1 and
demonstrated that the Co(III)-sb could be specifically targeted
by covalent attachment to an Sp1 recognition oligonucleotide.
MATERIALS AND METHODS
Synthesis of Cobalt Complexes. The syntheses of cobalt(III)-
Sb complexes were performed as described (6).
Synthesis of Oligonucleotides. Oligonucleotides were pre-
pared on an Applied Biosystems 394 synthesizer, with addition
of the phosporamidite of 29-amino-29-deoxyuridine as the
terminal base for the sense strand and deprotected overnight
at 55°C. DMT-29-N-trif luoroacetyl-protected phosphoramid-
ite was synthesized as reported (7). Oligonucleotides were
purified over C18 SepPak columns (Waters). Then, 12-cc
columns were washed twice with 20 ml of acetonitrile (EM
Science), three times with 20 ml of H2O, and loaded with up
to 1 mM DNA. Columns were washed three times with 20 ml
of water, and the sample was eluted with 60:40
(H2O:acetonitrile). DNA was detected by absorbance at 260
nm. Samples were dried on a speed vac (Savant SC110a).
Synthesis of Oligonucleotides Conjugates (Co-Oligonucle-
otides). Equimolar ratios of complement and sense strand in
TE buffer (10 mM TriszCl, 1 mM EDTA, pH 8.0) were
annealed by mixing, heating to 90°C, and cooling to room
temperature. This sample was exchanged to H2O over a
NAP-25 column and dried on a speed vac. One micromole of
the double-stranded oligonucleotide, with 29-aminouridine at
the 59 end, in 200 ml of 0.1 M Mes (Sigma), pH 4.5, was added
to 7.6 mg of Co(acacen)(NH3)2 (COBA)-acid in 500 ml of the
same buffer. This mixture was added to 38 mg of 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC;
Pierce) and reacted with gentle rocking overnight at room
temperature. The product was purified over a NAP-25 (Phar-
macia) column and dried on a speed vac. This sample then was
purified further over hydroxyapatite (to isolate duplex DNA)
in the batch mode (BioGel HTP DNA grade, Bio-Rad) with
stepwise elution in sodium phosphate from 0.01–0.40 M, pH
6.8. Fractions containing double-stranded DNA, as deter-
mined by absorbance at 260 nm and thermal denaturation
experiments, were desalted over C18 SepPak columns.
Synthesis of Peptides. The peptides were synthesized at the
Beckman Institute Biopolymer Synthesis Center at Caltech.
The automated stepwise solid-phase syntheses were per-
formed on an ABI 430A peptide synthesizer by using t-Boc
chemistry (8). OCH2-phenylacetamidomethyl (PAM) or
4-methylbenzhydrilamine resin (Applied Biosystems) were
used as a solid support. The side chain-protecting groups and
peptide-resin bonds of the completed peptides were cleaved by
using liquid anhydrous hydrofluonic acid in the presence of
p-cresol and p-thiocresol, as scavengers for 60 min at 0°C (9).
Peptides were purified by reverse-phase HPLC (HPLC liquid
chromatography) on a semipreparative C18 column (10 3 1
cm; Brownlee Lab) by using a linear gradient of 0–50%
aqueous acetonitriley0.1% trif luoroacetic acid (TFA) over 120
min. The purity and the primary structure of the peptides were
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determined by capillary electrophoresis and mass assisted laser
desorption ion time of flight (MALDI TOF) mass spectros-
copy. Isolated peptides revealed the presence of the homoge-
neous target sequence by all analytical methods used.
Gel Shift. 3.5 pmol of Sp1 oligonucleotide (or OCT 1,
CREB, CTFyNF1, AP1, GRE, and NF-kB, from Promega)
were labeled at the 59 end with ATP (Amersham) by T4
polynucleotide kinase using the manufacturer’s protocol
(GIBCOyBRL). Samples of labeled oligonucleotide were re-
moved and spotted to nitrocellulose before, and after purifi-
cation through G-25 Sephadex spin columns pre-equilibrated
with TE buffer (Boehringer Mannheim). Radioactivity bound
to the filters was assayed on a Beckman LS 1801 scintillation
counter. Labeling efficiency was calculated as percentage
incorporation equals post spin counts times volumeyprespin
counts times volume.
Then, 0.263 pmols (1 ml of 25 ngyml) of Sp1 transcription
factor were incubated at room temperature for 1 h in 20 ml of
gel-shift buffer A (25 mM Tris, pH 8.0y100 mM KCly2 mM
DTTy100 mM Zn Cl2y10% glyceroly50 mg/ml BSA); ref. 10) in
the presence or absence of 28 pmol cobalt complex (1 ml of 0.01
mgyml). Forty femptomoles of 32P-labeled oligonucleotide
were added to each reaction tube and incubated for 30 min at
room temperature. After 30 min, 2 ml of 0.1% bromophenol
blue was added to all tubes. The reaction mixtures were run on
4% polyacrylamide gels (80:1 acrylamide:bisacrylamide) in 0.5
mM Tris-boric acid-EDTA buffer (45 mM Triszboratey1 mM
EDTA), which had been prerun for 30 min before loading.
Gels were run at room temperature at 100 V and exposed to
x-ray film (Kodak X-Omat AR), with an intensifying screen,
overnight at 270°C and developed the following day.
Gel-shift assays by using cobalt–oligonucleotide conjugates
were performed as above with minor modifications. Samples
contained: 2 ml of 5x gel-shift buffer B [20% glyceroly5 mM
MgCl2y2.5 mM EDTAy2.5 mM DTTy250 mM NaCly50 mM
TriszHCl, pH 7.5y0.25 mg/ml poly(dI-dC)zpoly(dI-dC) (Pro-
mega)]; positive controls contained 2 ml of HeLa nuclear
extract from stock; experimental samples contained both
HeLa extract and 4 pmol cobalt–oligonucleotide conjugates,
and volume of all samples was adjusted to 9 ml with H2O. The
mixtures were incubated at room temperature for 10 min. Two
microliters of a 1:5 dilution from the appropriate radiolabeled
oligonucleotide was added to each sample, and the samples
were incubated for 20 min at room temperature. After 20 min,
1 ml of gel loading 10x buffer (250 mM Tris, pH 7.5y0.2%
bromophenol bluey0.2% xylene cyanoly40% glycerol) was
added to each reaction mixture, and the samples were loaded
to 4% polyacrylamide native gels. Gels were run at 150 V,
room temperature, then exposed to x-ray film, with an inten-
sifying screen, for 16 h at 270°C.
Filter Binding. Reaction mixtures were prepared as de-
scribed above for a range of concentrations of cobalt complex.
Samples were run in triplicate. After 30-min room temperature
incubation with radiolabeled oligonucleotide, the reaction
mixture was filtered through a nitrocellulose membrane (0.45
mm, Schleicher & Schull) under gentle suction; the tube was
rinsed once with 50 ml wash buffer, and the filter was washed
three times with 1 ml of wash buffer (10 mM Hepes, pH 7.5y1
mM EDTA, Promega protocol). Filters were dissolved in 9 ml
of Filtron-X scintillation fluid (National Diagnostics), and
radioactivity remaining on the filters was assayed on a Beck-
man LS 1801 scintillation counter.
To determine whether the binding of the conjugate was
irreversible, it was first necessary to determine the binding
saturation point for the amount of Sp1 used. One microliter of
Sp1 (at 25 ngyul from Promega) was incubated in 10 ml
gel-shift buffer A with increasing amounts of 32P-labeled Sp1
oligonucleotide. Saturation of binding occurred with 2 ml of
labeled oligonucleotide (0.6 pmol). The assays for irreversibil-
ity used this concentration of labeled Co-oligonucleotide or
oligonucleotide. Resistance of Co-oligonucleotide binding to
displacement by unlabeled oligonucleotide was assayed by
incubating 1 ml of Sp1 in 10 ml of gel-shift buffer A with 2 ml
of 32P-labeled Co-oligonucleotide or oligonucleotide. The
samples were incubated at room temperature for 20 min; then
excess unlabeled oligonucleotides (twofold) were introduced,
and the samples incubated an additional 2 h. Samples were
taken at various timepoints and analyzed by filter binding.
In a second assay to determine whether the conjugates
bound irreversibly to transcription factor Sp1, samples con-
taining 1 ml of Sp1, 10 ml of gel-shift buffer A, and 2 ml of 59
[32P]Co-oligonucleotide were allowed to incubate for 1.5 h at
room temperature. After incubation, one-half of the samples
were diluted with 90 ml of gel-shift buffer A and all samples
were left at room temperature an additional 1.5 h. Samples
were then assayed by filter binding.
CD Spectroscopy. Peptides were solubilized at a concentra-
tion of 0.125 mgyml in 25 mM phosphate buffer (pH 7.0) and
placed in a 0.1-mm path length quartz cuvette. Spectra were
averaged over eight scans from 260–195 nm on an Aviv 62DS
spectropolarimeter (Aviv Associates, Lakewood, NJ). A two-
fold molar excess of ZnCl2 was added and the spectra was
recorded again.
Inductively Coupled MS and Amino Acid Analysis. One
milligram of peptide in water was incubated with a molar
equivalent of ZnCl2 at room temperature for 10 min, and this
solution was added to 5 M equivalents of cobalt(III) complex
with axial ligands X 5 2-methylimidazole [Co(acacen)(2-
methylimidazole)2; COMI] or NH3 (COBA). The peptide and
cobalt complex mixture was incubated for 72 h at 4°C, placed
in a 1,000-MW cutoff membrane (Spectrum) and dialysed
against water at 4°C for 3 days. The amount of cobalt remain-
ing in the sample was determined by inductively coupled
plasma MS on a Perkin–ElmerySciex Elan 5000A. Peptide
content for the same sample was determined by amino acid
analysis on an Applied Biosystems 420a derivitizeryanalyzer.
This step was done for three different peptides: peptide 1,
VKCFNCGKEGHIARNCRA; peptide 2, ITNDLRLKDWE-
HSQTLKNIT; and peptide 3, LQFSIETLNGRVQENAFK-
QQ.
NMR. 1H NMR data were acquired on a Bruker AM-500 or
AMX-500 (T 5 30°C, 5 mM D2O; D 5 3H). Triplicate samples
were prepared by dissolving 3.5 mg of peptide in 350 ml of D2O
(Cambridge Isotope Laboratories, Cambridge, MA). One
molar equivalent of ZnCl2 (3 ml of 0.5 M solution) was added
to two of the samples; to one of these, 1 M equivalent of cobalt
complex (17.2 ml of 40 mgyml solution) also was added. The
pD of all samples was adjusted to 7.0 by using NaOD (Cam-
FIG. 1. Cobalt(III) complex of acacen. The substitution of an axial
ligand from cobalt(III) with a nitrogen from histidine results in a
Co(III)-His complex. This histidine is from a peptide or protein
containing a zinc finger domain. The complexes used in this work vary
in the nature of the axial ligands, X, and the group at position R.
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bridge Isotope Laboratories). COBA, in D2O (pD 7.19), was
titrated into a 2.47 mM solution of unfolded peptide1 in D2O
to a final cobalt complex:peptide ratio of 1:1. Spectra were
acquired after each addition of cobalt complex.
HPLC. Samples containing 1 mg of peptide in 1 ml of 0.001
M ZnCl2 (0.5 mM peptide) were prepared. Cobalt complexes
were added to a final concentration of 0.5 mM and contained
either axial ligand X 5 NH3 (COBA) or X 5 imidazole
(Co(acacen)(imidazole)2; COBI) as shown in Fig. 1. Samples
were passed through a cation exchange column (polyLC
sulfoethyl A) in 5 mM potassium phosphate and eluted with a
linear gradient of 0–500 mM KCl over 35 min.
4-(2-Pyridylazo)resorcinol (PAR) Assay for Zinc Release.
Peptides were solubilized in water at a concentration of 20 mM
in the presence of 20 mM ZnCl2 (EM Science), and PAR
(Sigma) was added to this solution to a final concentration of
0.1 mM. The absorbance at 500 nm of the peptide solution was
monitored on a Hewlett–Packard 8452a UV-Vis Spectropho-
tometer as acacen or cobalt complex (COBA or COMI) was
titrated into the solution (7.14 nmolyml for each addition).
Each sample was corrected against a blank containing 0.1 mM
PAR (no peptide), which was titrated in parallel. The amount
of zinc released by the peptide was determined by using DA500
5 6.6 3 104 M21zcm21.
RESULTS
Binding of Cobalt Complexes to a Model Zinc Finger
Peptide. The well known affinity of cobalt(III) for nitrogenous
ligands lead us to suspect that histidine residues in zinc fingers
could be suitable ligands. The peptide VKCFNCGKEG-
HIARNCRA and similar peptides have been extensively stud-
ied by numerous investigators as model zinc fingers (2, 11–17).
This peptide has been shown to adopt zinc finger-like structure
and bind double-stranded deoxyribonucleotides in solution
(18). To demonstrate that the Co(III)-sb were indeed capable
of binding to zinc finger peptides in a covalent manner, peptide
(folded about zinc)-cobalt complex mixtures were subjected to
HPLC separation on a cation exchange column under condi-
tions that would disrupt any noncovalent interactions (data not
shown). For these studies, we used COMI. COBI was used as
a control because this complex is substitutionally inert. Free
peptide eluted at 32 min, as did peptide in the presence of
COBI. In the presence of the reactive COMI complex, how-
ever, the peptide elution shifts. Some amount of free peptide
remains, but a large fraction of the peptide peak elutes '10
min earlier. These results indicate that only cobalt complex
with substitutionally active ligand binds covalently to peptide
and is consistent with axial ligand exchange of cobalt(III) as a
mechanism for binding.
To determine the stoichiometry of cobalt complex binding
to peptide, mixtures of peptide and COMI were subjected to
extensive dialysis to remove noncovalently bound complexes
and samples were removed for analysis of cobalt and peptide
content. As shown in Table 1, histidine-containing peptides
bound at least one cobalt complex whereas peptides without
histidine residues did not. Furthermore, the presence of lysine,
arginine, or cysteine residues did not influence the number of
cobalt complexes bound.
Effect of Cobalt Complexes on Zinc Finger Peptide Struc-
ture. We examined the peptide by CD spectropolarimetry to
verify that the peptide adopts a zinc finger structure in
solution. In the absence of zinc, the peptide displays a spec-
trum characteristic of typical random coil structure with an
intense negative band below 200 nm. Upon addition of zinc
(Fig. 2), this spectrum reveals b type II turn content charac-
teristic of zinc finger structures (17). The spectrum possesses
features that are analogous to those displayed by the metal-
loprotein rubidoxin and the polypeptide ala2-gly2, both known
to contain b type II turns (17), including minima at 185 nm and
227 nm and a maximum at 207 nm (19, 20). The ability of the
peptides to form zinc fingers in solution and the effect of cobalt
complexes on zinc finger structure were analyzed by NMR
spectroscopy and fluorescence assays.
NMR Spectroscopy. In the absence of zinc, the 1H NMR
spectrum of the unfolded peptide contains peaks at 7.91 and
7.08 ppm, characteristic of free histidine (Fig. 3a) which shift
in the presence of zinc to peaks at 7.58 and 7.01, which are
representative of metal bound histidine (Fig. 3b) (5). In
addition, the resolved multiplets indicate a stable tertiary
structure (5). Upon addition of COBA, this multiplet structure
is abolished. Over time, the spectrum in this region degrades
to a broad peak (Fig. 3c), indicating that cobalt complex
strongly perturbs the zinc finger structure.
To determine the mechanism for the loss of zinc finger
structure observed above, we performed titration studies.
Titration of COBA to the unfolded peptide results in a
disappearance of the imidazole proton peaks. As shown in Fig.
4, as cobalt complex is added to the peptide, the histidine peaks
at 6.98 and 7.79 ppm gradually disappear. New peaks appear
between 6.3 and 6.5 ppm. These results unambiguously dem-
onstrate binding of the cobalt complex to the imidazole side
chain.
PAR Assay. PAR has an absorbance at 400 nm in the
absence of zinc, which shifts to 500 nm when zinc is bound
(Zn(II)PAR2) (21). By monitoring the change in absorbance at
500 nm, we were able to detect the release of zinc from a model
zinc finger peptide upon interacting with cobalt complex. As
zinc is released from the peptide, it is free to bind PAR as
evidenced by an increase in the absorbance at 500 nm. Fig. 5
shows the change in absorbance at 500 nm as a function of
increasing concentrations of either acacen, COBA, or COMI.
It is evident that the addition of the equatorial ligand, acacen,
alone does not induce a change in the absorbance at 500 nm,
suggesting that no zinc is released by the peptide under these
conditions.
In contrast, as COBA or COMI is titrated into the peptide
solution, there is an increase in the absorbance at 500 nm,
which is complete after the addition of 2.5 equivalents of
COMI or 3.5 equivalents of COBA. The total increase in A500
of 0.886 after addition of COMI corresponds to the release of
FIG. 2. Eighteen amino acid peptide adopts zinc finger conforma-
tion in the presence of zinc. Peptides were examined by CD spec-
tropolarimetry (0.25 mM peptide in 25 mM phosphate buffer, pH 7.0)
in the presence and absence of zinc. In the absence of zinc, the spectra
is that of a typical random coil that changes upon the addition of zinc
to a spectra characteristic of zinc fingers, with b type II turn content.
Table 1. Stoichiometry of cobalt complex binding to peptides
Peptide Cobalt:peptide
VKCFNCGHEGHIARNCRA 1.44 6 0.3:1
ITNDLRLKDWEHSQTLKNIT 1.57 6 0.3:1
LQFSSIETLNGRVQENAFKQQ 1:469 6 55
Inductively coupled mass spectrometry and amino acid analysis were
used to determine the ratio of cobalt complexes bound to three
different peptides. The presence of lysine, arginine, or cysteine
residues does not influence the number of cobalt complexes bound.
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0.67 mol of zinc per mol of peptide, using DA500 5 6.6 3 104
M21zcm21 (22). Addition of COBA results in a DA500 of 0.480,
which corresponds to the release of 0.36 mol of zinc per mol
of peptide. These results confirm that cobalt(III) complexes
disrupt the structure of the model zinc finger peptide.
Effect of Cobalt Complexes on Zinc Finger Proteins. To
determine whether the binding of cobalt(III) complexes to
model peptides could be repeated with a full length zinc finger
protein, we investigated the effects of cobalt complexes on the
well characterized zinc finger protein Sp1 by using a gel-shift
assay. The binding of cobalt complex to histidine residues that
coordinate zinc should disrupt zinc finger structure and thus,
inhibit binding of the protein to DNA. Sp1 contains three zinc
finger-binding domains and recognizes the 6-bp consensus
sequence 59-GGGCGG. We used a commercially available,
22-bp oligonucleotide (Promega). Labeled oligonucleotide
was incubated in the presence or absence of Sp1 and various
amounts of cobalt complex, electrophoresed through a 4%
polyacrylamide native gel, and the gel was exposed to x-ray film
overnight. Free oligonucleotide migrates ahead of the larger
complex of oligonucleotide bound by protein (shifted band, as
shown in Fig. 6). It is evident that there is a loss of the shifted
band as the amount of cobalt complex increases from a 2- to
25-fold molar excess over the amount of Sp1. This result
indicates that cobalt chelate inhibits binding of Sp1 to its
recognition oligonucleotide in a concentration-dependent
manner.
To quantitate the degree of inhibition, samples were pre-
pared in triplicate and analyzed by filter-binding experiments.
Nitrocellulose filters bind protein but not DNA, so radioac-
tivity remaining on the filters reflects protein-bound oligonu-
cleotide. As the concentration of cobalt complex increases, the
FIG. 3. Cobalt(III) complex disrupts the structure of the zinc finger
peptide. 1H NMR data were acquired on a Bruker AM-500 (T 5 30°C,
5 mM D2O, pH 7.0); 3.5 mg of peptide were dissolved in 350 ml D2O
(Cambridge Isotope Laboratories), for each of the samples. Approx-
imately 1 M equivalent of ZnCl2 was added to the samples in a and b;
1 M equivalent of COBA also was added to c. In the absence of zinc
as shown in a, histidine peaks appear at 7.08 and 7.91, which shift upon
addition of zinc to those characteristic of metal bound histidine at 7.01
and 7.58 (b). Upon the addition of COBA, the spectrum degrades to
a broad peak (c), suggesting a strong perturbation to the structure of
the peptide.
FIG. 4. The cobalt(III) complex binds to a nitrogen of the imida-
zole ring. 1H NMR data were acquired on a Bruker AMX-500 (T 5
30°C, pH 7.19). Aliquots of COBI were titrated to a 2.47 mM solution
of unfolded peptide and incubated at room temperature for 1 h before
measurement. The final cobalt complex:peptide ratios are as follows:
0:1 (a), 0.33:1 (b), 0.67:1 (c), and 1:1 (d).
FIG. 5. Cobalt(III) complex causes the release of zinc from a zinc
finger peptide. Increasing molar equivalents of acacen (x), COBA
([irco]), or COMI () were added to a 20-mM solution of folded zinc
finger peptide in the presence of the zinc-binding dye, PAR. PAR
absorbs at 500 nm when zinc is bound and 400 nm in the absence of
zinc. Binding of cobalt complexes displaces zinc as evidenced by an
increase in the absorbance at 500 nm due to binding of free zinc by
PAR. This increase in absorbance is complete after addition of 2.5
equivalents of COMI, corresponding to the release of 0.67 mol of zinc
per mol of peptide. Titration with COBA is complete after 3.5
equivalents are added, corresponding to a release of 0.36 mol of zinc
per mol of peptide. There is no increase in absorbance upon addition
of acacen. All samples were corrected against a peptide-free blank
containing PAR titrated in parallel.
FIG. 6. Cobalt(III) complex inhibits the binding of Sp1 to its
recognition oligonucleotide. Sp1 was incubated with radiolabeled
recognition oligonucleotide in the presence of increasing amounts of
COBA as follows: lane 1, labeled oligonucleotide alone; lane 2, labeled
oligonucleotide 1 Sp1; lane 3, labeled oligonucleotide 1 Sp1 15 mM
COBA; lane 4, labeled oligonucleotide 1 Sp1 110 mM COBA; and
lane 5, labeled oligonucleotide 1 Sp1 150 mM COBA. The shifted
band disappears with increasing amounts of COBA.
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number of counts bound decreases, confirming the gel-shift
results(data not shown). Addition of as little as 0.1 mg of cobalt
complex (50% molar excess over amount of Sp1) reduced the
counts bound to background levels, indicating a complete
inhibition of Sp1 binding to the recognition oligonucleotide.
Therefore, we conclude that cobalt complex effectively inhibits
the function of Sp1.
Selective Inhibition of Zinc Finger Proteins. To selectively
inhibit the function of Sp1, we covalently attached Co(III)-sb
to the recognition oligonucleotide for Sp1. The free Co(III)-sb
complex can interact with any available histidines and has no
specificity for Sp1. We predicted that the attached oligonu-
cleotide would act to increase the local concentration of Co-sb
in the zinc finger region of the protein. Sp1 would bind to
oligonucleotide, and the proximity of Co-sb to histidine would
allow it to bind avidly. Likewise, the bulk of the attached
oligonucleotide should hinder interaction with other histidines
outside of the DNA-binding region.
We covalently attached the cobalt complex to the Sp1
recognition oligonucleotide by placing a 29-amino-29-
deoxyuridine residue at the 59 end of the oligo. This oligo was
reacted with a cobalt complex with carboxylic acid as the R
group (COBA-acid in Fig. 1). Gel filtration purified oligonu-
cleotide conjugates were then evaluated for specific inhibition
of Sp1 out of a mixture of many other transcription factors in
a HeLa nuclear extract system. Recognition oligonucleotides
for the DNA-binding proteins Sp1, OCT 1, CREB, CTF/NF1,
AP1, and NF-kB were labeled with 32P and individually
incubated with HeLa extract in the presence or absence of
cobalt-Sp1 oligonucleotide conjugates. The samples were sep-
arated by nondenaturing gel electrophoresis, and the autora-
diograph is shown in Fig. 7a. The three lanes for each of the
oligonucleotides represent: oligonucleotide alone, oligo plus
HeLa extract, and oligo plus HeLa plus COBA-oligo conju-
gate. Only in the lane corresponding to Sp1 is there a loss of
the shifted band in the presence of the COBA–oligonucleotide
conjugates.
Results of the gel-shift assays were confirmed, and the
degree of inhibition was quantitated by filter-binding experi-
ments (Fig. 7b). There was a 60% decrease in counts bound for
Sp1 in the presence of 15-fold M excess of COBA–
oligonucleotide conjugates. However, there is no significant
change for any of the other DNA-binding proteins. This result
demonstrates a selective inhibition of Sp1 when present in a
mixture of six other transcription factors, with no nonspecific
inhibition of other DNA-binding proteins.
Irreversible Inhibition of Zinc Finger Proteins. The binding
of cobalt complexes to the zinc finger protein Sp1 is irrevers-
ible. To determine which portion of the inhibition is caused by
binding of the cobalt complex and not by competitive inhibi-
tion by the conjugated oligonucleotides, we assayed for irre-
versible binding of the cobalt conjugates to Sp1. Inhibition
caused by cobalt complexes results from irreversible binding to
histidine residues (23) and thus, should be resistant to treat-
ments that would overcome a competitive inhibitor such as a
free oligonucleotide. For example, one of the traits of com-
petitive inhibition in enzymes is that inhibition can be over-
come by sufficient amounts of substrate. Similarly, a compet-
itively binding, labeled oligonucleotide should be displaced by
sufficient amounts of unlabeled oligonucleotide. Because it
was our intent to specifically evaluate the irreversibility of the
binding by Sp1, we chose to work with the purified Sp1 system
rather than with HeLa extract.
In competition experiments, the labeled oligonucleotide was
displaced more rapidly and completely than labeled cobalt–
oligonucleotide and the decrease in counts bound plateaued
2 h after introduction of unlabeled competitor. Results show
that 42.5 6 5.4% of the COBA–oligonucleotide remains
bound to Sp1 compared with 24.4 6 7.8% unmodified oligo-
nucleotide yielding a 90% confidence interval of a 14.6–20.7%
difference in the two values.
In addition, we used a dilution assay as a means to test for
irreversibility of the cobalt conjugate binding to Sp1. At
equilibrium, reversibly bound oligonucleotide should dissoci-
ate from Sp1 in dilute solutions whereas irreversibly bound
oligonucleotide will not. Sp1 oligonucleotide binding reduces
to near background levels (4 6 1%) after dilution, whereas
22.6 6 4.8% of COBA–oligonucleotide remains bound. It is
expected that some portion of the binding of COBA–
oligonucleotide is mediated through the oligonucleotide and is
reversible. These results produce a 90% confidence interval of
a 16.3–20.9% difference, which correlates with the results of
the competition studies.
DISCUSSION
Reactions of Co(III) Complexes with a Model Zinc Finger
Peptide. The results of our investigation clearly demonstrate
that the cobalt(III) complexes react with a model peptide and
disrupt zinc finger structure. Zinc finger peptide sequences
have been extensively used to characterize the mechanism of
DNA binding in glucocorticoid proteins (3), HIV nucleocapsid
protein (13–17), and to study folding, metal-binding, and
structure of zinc finger proteins (2, 14, 20, 24, 25). The first
retroviral zinc finger region from HIV-1 nucleocapsid protein
has been shown to form zinc finger-type structure in solution
and is DNA-binding competent (12, 13, 17). In these investi-
gations, CD and NMR verify that the peptide forms zinc
finger-type structure in solution and that this structure is
significantly perturbed by the binding of Co(III)-sb.
FIG. 7. COBA–oligonucleotide conjugates specifically inhibit Sp1.
(a) Gel-shift assay, samples were prepared as described in Materials
and Methods and run on 4% native polyacrylamide gels. Three lanes
appear for each binding protein: lane 1, containing labeled recognition
oligo alone; lane 2, labeled oligo 1 binding protein; and lane 3, labeled
oligo 1 binding protein 1 COBA–oligonucleotide conjugate. Only
lane 3 for Sp1 shows evidence of loss of shifted band in the presence
of COBA-oligo conjugate. (b) Filter-binding assay, samples were
prepared as in a and quantitated by filter-binding assays. Three lanes
containing: free oligonucleotide ‘, oligo 1 binding protein u, and
oligo 1 binding protein 1 COBA–oligonucleotide conjugate o are
shown for each of seven different DNA-binding proteins. Only Sp1
suffers a decrease of bound oligo in the presence of COBA–
oligonucleotide conjugate.
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In NMR studies, the gradual loss of the imidazole proton
peaks upon titration with the cobalt complex is clear evidence
that the complex is binding to a nitrogen of the imidazole ring.
This is supported by the results of the PAR assays, which
demonstrate that zinc is released by the zinc fingers in the
presence of cobalt complex, as would be expected if cobalt
complex bound to the histidine imidazole and displaced zinc.
Stoichiometric studies using inductively coupled plasma MS
and amino acid analysis demonstrate the covalent binding of
cobalt complexes to peptides containing histidine residues;
there is no significant binding to other peptides (see Table 1).
The ratio of cobalt to peptide is independent of the number of
lysine, arginine, or cysteine residues, indicating that these
residues are not involved in binding cobalt complexes. It is
important to note that the reduction potentials for the cobal-
t(III) complexes are too low to oxidize cysteines (6). Extensive
dialysis of the Co(III)-sb and peptide reaction mixtures does
not displace the complexes, suggesting that the binding of
cobalt complexes to the peptides is irreversible.
Reactions of Co(III) Complexes with Zinc Finger Protein
Sp1. We investigated the ability of Co(III)-sb to inhibit the
function of human transcription factor Sp1. Given the affinity
of Co(III)-sb for histidines, we believed that the complexes
would bind irreversibly to histidines in the zinc finger regions
of Sp1, displacing the zinc and abolishing DNA-binding activ-
ity. The results of gel-shift and filter-binding assays indicate
that Co(III)-sb effectively inhibits the binding of Sp1 to its
recognition oligonucleotide. These data and the results of the
peptide structural investigations demonstrate that the cobalt
complex disrupts zinc finger structure and thus prevents
binding of the protein to its recognition oligonucleotide.
Co-sb covalently attached to a recognition oligonucleotide
for Sp1 was able to specifically inhibit Sp1 binding without
inhibiting any of the other DNA-binding proteins examined.
Both competition with unlabeled oligonucleotide and dilution
were used to demonstrate covalent attachment of COBA to the
Sp1 for a fraction of the conjugates. The majority of the
binding appears to be reversible association with the oligonu-
cleotide portion of the conjugate.
This report demonstrates that cobalt(III) complexes have
significant effects on the structure and function of zinc finger-
mediated DNA-binding. This site of inhibition represents a
new target for antiviral agents. Antiviral agents have previ-
ously targeted the viral protein coat; however, the HIV virus
has eluded such drugs by rapid mutation. Subsequently, at-
tention was directed toward viral proteases and these treat-
ments seem to be meeting with some success (19, 20, 24). The
model peptide and protein used in our investigations are both
key components in viral replication. The peptide comes from
the zinc finger domain of the HIV nucleocapsid protein, a
highly conserved region that is essential for proper packaging
of HIV. The model protein selectively inhibited by Co(III)
complexes in this investigation, Sp1, has been implicated in the
activation of viral transcription. Cooperative interaction of Sp1
and NF-kB is required for stimulation of HIV-1 transcription,
and this interaction is due to specific binding of the amino-
terminal region of the RelA(p65) subunit to the zinc finger
region of Sp1 (25).
The only other small molecules known to act on zinc fingers
are a group of C-nitroso-substituted molecules that has been
reported to remove zinc from the nucleocapsid protein,
thereby disrupting the zinc finger domains, RNA packaging,
and viral infectivity in vitro (12, 24, 26). The same researchers
also report that a group of disulfide-substituted benzamides
inhibits HIV nucleocapsid zinc fingers. These compounds are
believed to oxidatively attack the cysteine thiolates of the zinc
finger motif. It was proposed that the compounds selectively
act on retroviral-type zinc fingers (CCHC) such as those on the
nucleocapsid protein and do not act on the classical-type zinc
fingers (CCHH) found in the other proteins. The mode of
action for such discrimination is undetermined, and the effects
of the drugs on eukaryotic proteins containing classical-type
fingers have not been shown.
Our investigations demonstrate that cobalt(III) complexes
bind to histidine residues of zinc finger domains and can inhibit
selected transcription factors when conjugated to the recog-
nition oligonucleotide for that protein. These complexes in-
troduce a method for inhibition of zinc finger proteins which
may be exploited for the treatment of various diseases.
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